Gonick H C, Weiler E, Khalil-Manesh F
Klin Wochenschr. 1987;65 Suppl 8:139-45.
The pattern of endogenous Na-K-ATPase inhibitors in plasma and urine from patients with essential hypertension and normal controls was established by sequential Amicon ultrafiltration through membranes with molecular weight cut-offs of 50 K daltons, 30 K daltons and 1 K daltons, followed by C18 Sep-Pak cartridge separation of the 1 K filtrate. Significantly increased Na-K-ATPase inhibitory activity in the hypertensive population was found in a high molecular weight (30-50 K daltons) urine fraction, one low molecular weight (less than 1 K daltons) urine fraction and two low molecular weight plasma fractions. Preliminary evidence is presented to suggest that large molecular weight plasma fractions may contain a "masked" Na-K-ATPase inhibitor, in either carrier or precursor form.
通过使用截留分子量分别为50千道尔顿、30千道尔顿和1千道尔顿的膜进行连续的Amicon超滤，随后对1千道尔顿的滤液进行C18 Sep-Pak柱分离，确定了原发性高血压患者和正常对照者血浆及尿液中内源性钠钾ATP酶抑制剂的模式。在高血压人群中，在高分子量（30 - 50千道尔顿）尿液组分、一个低分子量（小于1千道尔顿）尿液组分和两个低分子量血浆组分中发现钠钾ATP酶抑制活性显著增加。初步证据表明，高分子量血浆组分可能含有载体或前体形式的“隐蔽”钠钾ATP酶抑制剂。
